The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.
The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback